Wiley Bros. Aintree Capital, LLC Gilead Sciences, Inc. Transaction History
Wiley Bros. Aintree Capital, LLC
- $9.13 Billion
- Q1 2025
A detailed history of Wiley Bros. Aintree Capital, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Wiley Bros. Aintree Capital, LLC holds 101,601 shares of GILD stock, worth $11.2 Million. This represents 0.12% of its overall portfolio holdings.
Number of Shares
101,601
Previous 98,329
3.33%
Holding current value
$11.2 Million
Previous $9.08 Million
25.35%
% of portfolio
0.12%
Previous 0.11%
Shares
7 transactions
Others Institutions Holding GILD
# of Institutions
2,289Shares Held
997MCall Options Held
9.62MPut Options Held
10M-
Black Rock Inc. New York, NY121MShares$13.4 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA117MShares$13 Billion0.25% of portfolio
-
State Street Corp Boston, MA59.5MShares$6.59 Billion0.28% of portfolio
-
Capital Research Global Investors Los Angeles, CA54.6MShares$6.04 Billion1.39% of portfolio
-
Capital World Investors Los Angeles, CA53.5MShares$5.93 Billion1.01% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $139B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...